Navigation Links
Bioniche Pharma and Synerx Pharma Launch Fomepizole Injection

LAKE FOREST, Ill., Sept. 24 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Synerx Pharma, LLC, announced today the launch of Fomepizole Injection, the generic equivalent of Antizol(R) from Paladin Labs, Inc.


"The addition of Fomepizole to Bioniche's product offering further broadens our base of niche injectables," said George Zorich, President, US Operations for Bioniche Pharma.

Bioniche Pharma and Synerx Pharma entered into a definitive agreement whereby Bioniche Pharma has the rights to market and distribute Fomepizole in the United States.

Bioniche will supply Fomepizole Injection in 1.5g /1.5 mL vials.

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets. The company's growth is fueled by an internal development pipeline and an aggressive acquisition strategy for products. Bioniche Pharma was acquired in February 2006 by RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois. More information about Bioniche Pharma can be found at

About Synerx Pharma:

Synerx Pharma, LLC is a privately held corporation located in historic Bucks County Pennsylvania. Established in January 2004, the company develops and brings to market select pharmaceutical products aimed at addressing unmet market needs, particularly those involving some combination of barriers to entry. The company focuses on developing cost effective specialty generic pharmaceuticals and small brand products. Synerx presently has six FDA approved products, of which four were First Time Generic Approvals, and a development portfolio of ten projects at various stages of development in multiple dosage forms. More information can be found at

Antizol(R) is a registered trademark of Paladin Labs.

SOURCE Bioniche Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Reports Fiscal 2009 Year-End Results
2. Bioniche Phase III Clinical Trial with Urocidin(TM) Given Continued Green Light by DMC
3. Bioniche Repays Revolving Credit Facility
4. Bioniche Provides a Corporate Update
5. Bioniche Pharma and Synerx Pharma Launch Melphalan Hydrochloride for Injection
6. Bioniche Represented at House of Commons Sub-Committee on Food Safety
7. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
8. Bioniche Reports Fiscal 2009 Third Quarter
9. Bioniche Provides a Corporate Update
10. Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
11. Bioniche Revolving Credit Facility Maturity Date Amended
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... On ... holding a treadmill relay – Miles by Moonlight to raise money for the American ... $300 or more. , Teams will work together to keep their treadmills moving ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical Officer ... physician colleagues, skilled nursing facility medical directors and other clinicians at various events ... Care." , "At many of these conferences we get to educate other physicians, ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... -- Caris Life Sciences ® , a leading innovator in ... medicine, today announced that St. Jude Medical Center,s Crosson ... as its 17 th member. Through participation with ... Institute will help develop standards of care and best ... cancer treatment more precise and effective. ...
(Date:10/7/2017)... , Oct. 6, 2017   Provista, ... more than $100 billion in purchasing power, today announced ... and information. The Newsroom is the online ... industry trends, infographics, expert bios, news releases, slideshows and ... access to a wealth of resources at their fingertips, ...
(Date:10/2/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ... LLC , and named its founder as Diplomat,s chief ... Tennessee , will operate under Diplomat subsidiary ... offerings for health care partners to include IT outsourcing, ... "In an interoperable world, technology delivers comprehensive insight ...
Breaking Medicine Technology: